PT  - JOURNAL ARTICLE
AU  - Paul, Sarah E.
AU  - Hatoum, Alexander
AU  - Fine, Jeremy D.
AU  - Johnson, Emma C.
AU  - Hansen, Isabella
AU  - Karcher, Nicole R.
AU  - Moreau, Allison L.
AU  - Bondy, Erin
AU  - Qu, Yueyue
AU  - Carter, Ebony B.
AU  - Rogers, Cynthia E
AU  - Agrawal, Arpana
AU  - Barch, Deanna M.
AU  - Bogdan, Ryan
TI  - Prenatal cannabis exposure and childhood outcomes: Results from the ABCD study
AID  - 10.1101/2019.12.18.19015164
DP  - 2019 Jan 01
TA  - medRxiv
PG  - 2019.12.18.19015164
4099  - http://medrxiv.org/content/early/2019/12/19/2019.12.18.19015164.short
4100  - http://medrxiv.org/content/early/2019/12/19/2019.12.18.19015164.full
AB  - Importance In light of increasing cannabis use among pregnant women, the Surgeon General of the United States issued an advisory against the use of marijuana during pregnancy on August 29th, 2019.Objective To determine whether cannabis use during pregnancy is associated with adverse outcomes among offspring.Design Cross-sectional analysis of the baseline session of the ongoing longitudinal Adolescent Brain and Cognitive Development (ABCD) study.Setting Data were collected from 22 sites across the United States between 2016 and 2018.Participants Children ages 9-11 (n=11,489) and their parent or caregiver.Exposure Prenatal marijuana exposure prior to and following maternal knowledge of pregnancy.Main Outcomes and Measures Child psychopathology symptomatology (i.e., psychotic-like experiences and internalizing, externalizing, attention, thought, and social problems), cognition, sleep, birth weight, gestational age at birth, body mass index (BMI), and brain structure (i.e., total intracranial volume, white matter volume, gray matter volume). Covariates included familial (e.g., income, familial psychopathology), pregnancy (e.g., prenatal vitamin use, whether the pregnancy was planned), and child (e.g., birth weight, substance use) variables.Results Among 11,489 children (age 9.9±0.6 years; 47.78% female), 655 (5.70%) were prenatally exposed to cannabis in total. Marijuana use prior to (n=648; 5.64%) and following (n=242; 2.11%) maternal knowledge of pregnancy were associated with increased offspring psychopathology characteristics (i.e., psychotic-like experiences and internalizing, externalizing, attention, thought, social, and sleep problems) and BMI as well as reduced cognition, birth weight, and brain structure (i.e., total white and gray mater volumes; all psfdr<.007), but not gestational age at birth. Exposure following maternal knowledge of pregnancy remained significantly associated with psychopathology, cognition, and birth weight outcomes when including potentially confounding variables (all ps<0.046). All associations with exposure prior to maternal knowledge of pregnancy were nonsignificant when considering potentially confounding variables (all ps>0.06).Conclusions and Relevance Prenatal cannabis exposure, and its correlated factors, may increase risk for psychopathology and reduced cognition during middle childhood as well as reduced birthweight. Consistent with recent recommendations by the Surgeon General, marijuana use during pregnancy should be discouraged.Competing Interest StatementThe authors have declared no competing interest.Funding StatementData for this study were provided by the Adolescent Brain Cognitive Development (ABCD) study which was funded by awards U01DA041022, U01DA041025, U01DA041028, U01DA041048, U01DA041089, U01DA041093, U01DA041106, U01DA041117, U01DA041120, U01DA041134, U01DA041148, U01DA041156, U01DA041174, U24DA041123, and U24DA041147 from the NIH and additional federal partners (https://abcdstudy.org/federal-partners.html). Authors received funding support from NIH: Dr. Hatoum (T32-DA007261), Dr. Johnson (F32 AA027435), Dr. Karcher (MH014677), Dr. Carter (R01-DA046224), Dr. Rogers (R01-DA046224), Dr. Agrawal (5K02DA32573; R01-DA046224), Dr. Barch (R01-MH113883; R01-MH066031; U01-MH109589; U01-A005020803; R01-MH090786), Dr. Bogdan (R01-AG045231, R01-HD083614, R01-AG052564, R21-AA027827, R01-DA046224).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData came from the ABCD study 2.0.1 data release. More information about this study and how to access these data are available here: https://abcdstudy.org/